PP
ACUR

Paloma Partners’s Acura Pharmaceuticals ACUR Stock Holding History

Paloma Partners’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-10,436
Closed -$98K – 1349
2013
Q2 		$98K Buy
+10,436
New +$118K 0.01% 1066

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CA
Cortland Associates St Louis, Missouri $697M AUM 4.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Paloma Partners's ACUR Position: Q3 2013 in Review

Paloma Partners sold out of Acura Pharmaceuticals (ACUR) in Q3 2013, closing a stake of 10,436 shares — an estimated $98K sold.

Paloma Partners first reported a position in ACUR in Q2 2013 and held it in 1 quarter. The position peaked at $98K in Q2 2013. 30 funds tracked by Wall St. Rank hold ACUR as of Q3 2013.

  • Paloma Partners reported no remaining Acura Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Paloma Partners sold 10,436 Acura Pharmaceuticals shares in Q3 2013, an estimated $98K.
  • Paloma Partners first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Paloma Partners's Acura Pharmaceuticals position peaked at $98K in Q2 2013.
  • 30 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2013.

Based on Paloma Partners's 13F filing for Q3 2013, filed 14 Nov 2013.